#USA #New York #Levi Korsinsky #Rocket Pharmaceuticals #RCKT

Rocket Pharmaceuticals, Inc. Faces Class Action Lawsuit

Overview

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is currently embroiled in a significant legal battle as a class action lawsuit alleging securities law violations has been filed against the company. The lawsuit, brought forth by Levi & Korsinsky LLP, centers on the claims that Rocket engaged in misleading and fraudulent activities that adversely impacted investors.

Class Action Details

The lawsuit's class definition includes all investors who purchased shares of Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025. The plaintiffs claim that during this period, the company provided optimistic statements about its flagship product, RP-A501. However, they failed to disclose critical information regarding the safety and clinical trial protocols related to the drug.

Particularly alarming is the claim that the company concealed serious adverse events (SAEs) that occurred during clinical trials, including the death of participants. It is alleged that Rocket amended its clinical trial protocol to incorporate a new immunomodulatory agent without properly informing investors of these changes. It is suggested that these actions led investors to buy Rocket's stock at inflated prices, severely impacting their financial standing once the truth came to light.

Critical Events

The turning point came on May 27, 2025, when Rocket announced that the FDA imposed a clinical hold on the RP-A501 Phase 2 pivotal study due to critical issues that arose. This announcement followed the compounding of SAEs, including patient mortality, which occurred after the company had made undisclosed adjustments to its trial protocol. After the announcement, the stock's value plummeted from $6.27 per share on May 23 to $2.33 by May 27, reflecting a staggering 37% decrease in a single trading day. This drastic fall has raised concerns among shareholders regarding the company’s transparency and adherence to securities regulations.

Call to Action for Affected Investors

Affected investors have until August 11, 2025, to file their requests for lead plaintiff status in the ongoing lawsuit. Importantly, those who qualify for this class action do not have to be lead plaintiffs to be eligible for compensation; participation could still lead to recovery for losses incurred.

Levi & Korsinsky LLP assures potential class members that there will be no out-of-pocket expenses for participating in the lawsuit. This assurance reflects their commitment to representing investors diligently without imposing financial burdens during these challenging times.

Why Choose Levi & Korsinsky

With a distinguished track record in securities litigation spanning over two decades, Levi & Korsinsky has successfully secured numerous settlements and verdicts amounting to hundreds of millions of dollars for their clients. They boast a specialized team, maximizing their ability to provide effective representation and navigate the complexities of securities law violations. Furthermore, for seven consecutive years, they have ranked among the top securities litigation firms in the United States according to ISS Securities Class Action Services.

In sum, this lawsuit serves as a stark reminder of the risks involved in investing within the pharmaceutical sector, particularly when transparency is called into question. Investors are urged to proceed with caution and seek guidance from legal professionals experienced in these matters.

Contact Information
For additional details regarding the lawsuit or to express your interest in participation, interested parties are encouraged to reach out directly to Joseph E. Levi, Esq. at Levi & Korsinsky, LLP, via email or telephone.

• ---

Contact:
Joseph E. Levi, Esq.
Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500